Action Sanofi - SNY

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

54,03

Prix Achat

54,00

Prix Vente

54,04

Volume échangé

4 684

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Cap du marché

136,493B

Clôture Veille

54,14

Ouverture

Dernière Transaction

300

54.03

(formt)

Dernière heure de transaction

12:42:36

Volume financier

VWAP

Volume moyen (3 m)

Actions en circulation

2 526 245 442

Rendement du Dividende

7.29%

Ratio Cours sur Bénéfices

47,21

Bénéfice par action (BPA)

2,2

Chiffre d'affairess

46,11B

Bénéfice net

5,56B

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company... Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue. Show more

Secteur

Health & Allied Services,nec

Industrie

Pharmaceutical Preparations

Site Web

www.sanofi.com

Siège social

Paris, Paris, Fra

Fondé

1994

Sanofi est coté dans le secteur Health & Allied Services de la NASDAQ avec le ticker SNY. Le dernier cours de clôture d'Sanofi était de US$54,14. Au cours de la dernière année, les actions de Sanofi ont été négociées dans une fourchette de prix de US$ 0,00 à US$ 0,00.

Sanofi compte actuellement 2 526 245 442 actions en circulation. La capitalisation boursière d'Sanofi est de US$136,77 milliard. Sanofi a un ratio cours/bénéfice (ratio PE) de 47.21.

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all...

Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).

Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

SNY - Frequently Asked Questions (FAQ)

What is the current Sanofi share price?

The current share price of Sanofi is US$ 54,03

How many Sanofi shares are in issue?

Sanofi has 2 526 245 442 shares in issue

What is the market cap of Sanofi?

The market capitalisation of Sanofi is USD 136,77B

What is the 1 year trading range for Sanofi share price?

Sanofi has traded in the range of US$ 0,00 to US$ 0,00 during the past year

What is the PE ratio of Sanofi?

The price to earnings ratio of Sanofi is 47,21

What is the cash to sales ratio of Sanofi?

The cash to sales ratio of Sanofi is 5,69

What is the reporting currency for Sanofi?

Sanofi reports financial results in EUR

What is the latest annual turnover for Sanofi?

The latest annual turnover of Sanofi is EUR 46,11B

What is the latest annual profit for Sanofi?

The latest annual profit of Sanofi is EUR 5,56B

What is the registered address of Sanofi?

The registered address for Sanofi is 46, AVENUE DE LA GRANDE ARMEE, PARIS, PARIS, 75017

What is the Sanofi website address?

The website address for Sanofi is www.sanofi.com

Which industry sector does Sanofi operate in?

Sanofi operates in the PHARMACEUTICAL PREPARATIONS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
STAKSTAK Inc	US$ 3,58 (130,97%)	106
PMAXPowell Max Ltd	US$ 0,64 (79,78%)	26,15M
BONBon Natural Life Ltd	US$ 1,44 (51,58%)	69
BSCSInvesco Bulletshares 2028 Corporate Bond ETF	US$ 29,99 (47,66%)	1
CBUSCibus Inc	US$ 2,82 (47,64%)	1
SPGCSacks Parente Golf Inc	US$ 0,2043 (-49,68%)	6,41M
NVNINVNI Group Ltd	US$ 1,20 (-40,00%)	107,93k
MBIOMustang Bio Inc	US$ 1,99 (-27,37%)	6,02k
DCGODocGo Inc	US$ 2,97 (-24,23%)	35,78k
DLODLocal Ltd	US$ 10,84 (-21,16%)	8,78k
PMAXPowell Max Ltd	US$ 0,64 (79,78%)	26,15M
VRPXVirpax Pharmaceuticals Inc	US$ 0,272 (19,72%)	25,51M
ARBBARB IOT Group Ltd	US$ 0,70 (45,83%)	9,2M
SPGCSacks Parente Golf Inc	US$ 0,2043 (-49,68%)	6,41M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 12,35 (-0,96%)	5,83M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Sanofi (SNY) Cours

Sanofi (SNY)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Sanofi

SNY Dernières nouvelles

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)

Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)

Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis

Capri Shares Crash 45% After Merger Block; Coursera Falls 18% on Lower Revenue Forecast

Spirit’s Stock Surges 56% on Refinancing; Starboard Invests in Kenvue; Cigna-Humana Merger Back in Negotiations

SNY - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR